home
science
team
news
contact
✕
31 Maggio 2023
Business Wire – 31/05/2023
IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
13 Gennaio 2023
Business Wire – 12/01/2023
IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
26 Luglio 2022
Business Wire – 27/07/22
IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
29 Giugno 2022
Business Wire – 29/06/22
IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
24 Maggio 2022
Business Wire – 24/05/22
IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
31 Marzo 2022
Business Wire – 31/03/22
IAMA Therapeutics Announces Formation of Scientific Advisory Board
11 Febbraio 2022
Business Wire – 29/03/22
IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
IAMA Therapeutics S.r.l.
iamatherapeutics@legalmail.it
Vat: 02775040997
Address
Via Filippo Turati, 2
16128 Genoa Italy
Contact
info@iamatherapeutics.com
Cookie Policy
-
Privacy Policy
Powered by Hetaweb
-
www.hetaweb.it